Despite the door being opened for generic competition to Restasis more than a year, no FDA approvals for ANDAs referencing the eye-disease drug have been forthcoming. However, that could change before the year is out.

Fresenius Kabi is looking to make headway into biosimilars but saw its progress limited by COVID-19 in Q2. Management gave an update on the company’s endeavors during the Q2 earnings call, including key tender victories.

Fresenius Kabi says a decision on damages stemming from its aborted takeover of troubled Akorn is expected imminently, but has underlined it will not reap enormous riches with a victory. Meanwhile, the German firm has just initiated Phase III trials for a key biosimilar candidate.